DBV Technologies S.A. (DBVT)
Company Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis.
Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes.
The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Country | FR |
IPO Date | Oct 22, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 109 |
CEO | Daniel Tassé |
Contact Details
Address: 177-181 Avenue Pierre Brossolette Montrouge, FR | |
Website | https://www.dbv-technologies.com |
Stock Details
Ticker Symbol | DBVT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001613780 |
CUSIP Number | 23306J101 |
ISIN Number | US23306J1016 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Daniel Tassé | Chief Executive Officer & Director |
Michele F. Robertson | Chief Legal Officer |
Virginie Simone Jeanine Verrechia Boucinha M.B.A. | Chief Financial Officer & Principal Accounting Officer |
Alan Kerr | Senior Vice President & Head of Global Regulatory Affairs |
Caroline Daniere | Chief Human Resources Officer & Chief of Staff |
Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer |
Dr. Pharis Mohideen | Chief Medical Officer |
Dr. Wence Agbotounou | Chief Clinical Trial Officer & Senior Vice President |
Edward P. Jordan M.B.A. | Senior Vice President of Commercial Operations North America |
Katie Matthews | Investor Relations Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 30, 2025 | 8-K | Current Report |
Apr 30, 2025 | 10-Q | Quarterly Report |
Apr 28, 2025 | 10-K/A | [Amend] Annual Report |
Apr 24, 2025 | 3 | Filing |
Apr 17, 2025 | D | Filing |
Apr 14, 2025 | SCHEDULE 13G | Filing |
Apr 11, 2025 | SCHEDULE 13G | Filing |
Apr 08, 2025 | SCHEDULE 13G | Filing |
Apr 07, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Apr 07, 2025 | 3 | Filing |